KR20200031990A - Composition for inhibiting a formation of biofilm - Google Patents
Composition for inhibiting a formation of biofilm Download PDFInfo
- Publication number
- KR20200031990A KR20200031990A KR1020190102815A KR20190102815A KR20200031990A KR 20200031990 A KR20200031990 A KR 20200031990A KR 1020190102815 A KR1020190102815 A KR 1020190102815A KR 20190102815 A KR20190102815 A KR 20190102815A KR 20200031990 A KR20200031990 A KR 20200031990A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- oil
- biofilm formation
- tooth
- inhibiting biofilm
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 230000002401 inhibitory effect Effects 0.000 title claims description 23
- 230000015572 biosynthetic process Effects 0.000 title abstract description 9
- 239000004094 surface-active agent Substances 0.000 claims abstract description 20
- 210000000214 mouth Anatomy 0.000 claims abstract description 14
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 12
- 239000008158 vegetable oil Substances 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 230000032770 biofilm formation Effects 0.000 claims description 18
- 239000003240 coconut oil Substances 0.000 claims description 18
- 235000019864 coconut oil Nutrition 0.000 claims description 18
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 18
- 239000003921 oil Substances 0.000 claims description 18
- 235000019198 oils Nutrition 0.000 claims description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 150000004665 fatty acids Chemical class 0.000 claims description 15
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 14
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 12
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 9
- 235000021355 Stearic acid Nutrition 0.000 claims description 9
- 239000003945 anionic surfactant Substances 0.000 claims description 9
- 229960000541 cetyl alcohol Drugs 0.000 claims description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 9
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 9
- 239000004006 olive oil Substances 0.000 claims description 9
- 235000008390 olive oil Nutrition 0.000 claims description 9
- 229950011392 sorbitan stearate Drugs 0.000 claims description 9
- 239000008117 stearic acid Substances 0.000 claims description 9
- 229940034610 toothpaste Drugs 0.000 claims description 9
- 239000000606 toothpaste Substances 0.000 claims description 9
- 239000002736 nonionic surfactant Substances 0.000 claims description 8
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 7
- DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 239000008169 grapeseed oil Substances 0.000 claims description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 5
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 claims description 5
- 229940048848 lauryl glucoside Drugs 0.000 claims description 5
- 239000002324 mouth wash Substances 0.000 claims description 5
- 229940051866 mouthwash Drugs 0.000 claims description 5
- 235000020238 sunflower seed Nutrition 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000019612 pigmentation Effects 0.000 claims description 3
- 230000002087 whitening effect Effects 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims 1
- 230000007794 irritation Effects 0.000 abstract description 16
- 238000004040 coloring Methods 0.000 abstract description 10
- 230000003020 moisturizing effect Effects 0.000 abstract description 7
- 239000004088 foaming agent Substances 0.000 abstract description 4
- 230000000774 hypoallergenic effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 56
- 238000009472 formulation Methods 0.000 description 23
- 238000011156 evaluation Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 11
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 8
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 8
- 239000006072 paste Substances 0.000 description 8
- 208000028169 periodontal disease Diseases 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 235000013599 spices Nutrition 0.000 description 7
- 208000002925 dental caries Diseases 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 229940091249 fluoride supplement Drugs 0.000 description 5
- 201000001245 periodontitis Diseases 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229960004029 silicic acid Drugs 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- 229940045944 sodium lauroyl glutamate Drugs 0.000 description 5
- IWIUXJGIDSGWDN-UQKRIMTDSA-M sodium;(2s)-2-(dodecanoylamino)pentanedioate;hydron Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC(O)=O IWIUXJGIDSGWDN-UQKRIMTDSA-M 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 206010016322 Feeling abnormal Diseases 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 235000013353 coffee beverage Nutrition 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000007565 gingivitis Diseases 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- -1 Chlorohydroxy Aluminum Chemical compound 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000005888 Periodontal Pocket Diseases 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- 238000012459 agar diffusion assay Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000002379 periodontal ligament Anatomy 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000015109 caffè americano Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/596—Mixtures of surface active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
- A61K2800/72—Hypo-allergenic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 저자극성이면서 구강 내 또는 치아 표면에 바이오필름이 생성되는 것을 억제하는 조성물에 관한 것으로서, 보다 상세하게는 식물성 오일을 함유함으로써 치아를 코팅하여 바이오필름 형성을 억제하고 치아 착색을 예방하며, 기포제로 사용되는 계면활성제에 의한 자극을 완화시키면서, 입술 보습에도 효과적인 조성물, 구체적으로는 구강용 조성물에 관한 것이다.The present invention relates to a composition that suppresses the formation of biofilms in the oral cavity or on the tooth surface while being hypoallergenic, more specifically, by coating the teeth by containing vegetable oil to inhibit biofilm formation and prevent tooth coloring, It relates to a composition that is effective in moisturizing the lips while reducing the irritation caused by the surfactant used as a foaming agent, specifically, a composition for oral cavity.
치아는 인산칼슘(Calcium phosphate)으로 이루어진 무기질로서, 이와 관련된 질환으로는 크게 충치와 치주질환이 있다. 이 중 충치는 어린이부터 성인까지 치과질병의 가장 큰 부분을 차지하고 있으며 발생빈도가 높아지고 있다. 대한치과의사협회의 보고에 따르면, 아동의 90% 이상이 치아 우식(Dental caries)을 경험하며, 성인의 80% 이상이 잇몸질환을 갖고 있다고 한다. 이런 질환을 일으키는 주요한 원인은 구강내의 미생물에 의한 감염으로 세균, 음식물, 타액의 상호작용에 의해 유발된다. 즉, 구강 내 세균의 발육에 필요한 영양분과 수분이 음식물과 타액, 치은열구액 등에 의하여 계속 공급되고 구강내의 환경이 미생물이 발육하기에 적합한 온도(37℃pH(중성 부근)를 갖는다.Tooth is a calcium phosphate (Calcium phosphate) mineral, and related diseases are largely decayed and periodontal disease. Among them, tooth decay is the largest part of dental diseases from children to adults, and the incidence is increasing. According to a report by the Korean Dental Association, more than 90% of children experience dental caries, and more than 80% of adults have gum disease. The main cause of this disease is infection by microorganisms in the oral cavity, which is caused by the interaction of bacteria, food, and saliva. That is, the nutrients and moisture necessary for the growth of bacteria in the oral cavity are continuously supplied by food, saliva, gingival fissure, etc., and the environment in the oral cavity has a temperature (37 ° C. pH (near neutral) suitable for microorganisms to develop.
치주질환을 유발하는 대표적인 미생물로 스트렙토코커스 뮤탄스(Streptococcus mutans)와 플레보텔라 인터메디아(Prevotella intermedia)가 있다. 이런 미생물들은 음식물 내에 존재하는 자당(Sucrose)을 포도당(Glucose)과 과당(Fructose)으로 생성하는 미생물 대사과정을 일으켜 포도당의 중합체인 불용성 글루칸(Glucan)을 치면에 형성한다. 이러한 과정에서 글루칸에 의해 구강 내 다른 미생물들과 치면에 부착하여 치면 바이오필름(biofilm), 즉 플라그(Dental plaque)가 형성된다. 형성된 플라그의 내부에 스트렙토코커스 뮤탄스를 포함한 젖산균에 의해 축적된 젖산이 치아표면의 에나멜을 용해시켜 충치가 발생된다. 또한 그러한 각종균의 증식에 따른 산물들에 의해 치조골이 용해되므로 치주질환이 발생되게 된다.Representative microorganisms that cause periodontal disease include Streptococcus mutans and Prevotella intermedia. These microorganisms cause microbial metabolism that produces sucrose present in food into glucose and fructose, forming insoluble glucan, a polymer of glucose, on the tooth surface. In this process, glucan attaches to other teeth and other microbes in the oral cavity to form a biofilm, ie, a dental plaque. The lactic acid accumulated by the lactic acid bacteria including Streptococcus mutans inside the formed plaque dissolves the enamel on the tooth surface, causing cavities. In addition, alveolar bone is dissolved by the products resulting from the proliferation of various bacteria, so that periodontal disease occurs.
치주질환은 흔히 풍치라고도 하는데, 병의 정도에 따라 치은염(gingivitis)과 치주염(periodontitis)으로 나뉜다. 비교적 가볍고 회복이 빠른 형태의 치주질환으로 잇몸 즉, 연조직에만 국한된 형태를 치은염이라고 하고, 이러한 염증이 잇몸과 잇몸뼈 주변까지 진행된 경우를 치주염이라고 한다.Periodontal disease is often referred to as pungchi, depending on the severity of the disease is divided into gingivitis (gingivitis) and periodontitis (periodontitis). Periodontitis is a periodontal disease of relatively light and rapid recovery that is limited to the gums, ie, soft tissue, and is called gingivitis.
또한 치은(잇몸)과 치아 사이에 V자 모양의 틈이 있는데, 치주질환은 이 홈(sulcus)의 잇몸 선 아랫부분을 세균이 공격하여 치주인대와 인접조직을 손상시키는 것을 말한다. 염증이 진행되어 더 많은 조직이 손상되면서 홈이 치주낭(periodontal pocket)으로 발전하게 되며, 치주염이 심할수록 치주낭의 깊이가 깊어지게 된다. 치주낭이 깊어지면서 치주인대에 염증이 생기게 되고 골소실이 일어나기도 한다.In addition, there is a V-shaped gap between the gingiva (gum) and the teeth. Periodontal disease refers to the damage of the periodontal ligament and adjacent tissues by bacteria attacking the lower part of the gum line of this groove. As inflammation progresses and more tissue is damaged, the groove develops into a periodontal pocket, and the deeper the periodontitis, the deeper the depth of the periodontal pocket. As the periodontal sap deepens, the periodontal ligament becomes inflamed and bone loss occurs.
상기 충치 및 치주질환을 억제하기 위해서 항균물질인 소듐 바이카보네이트(NaHCO3), 트리클로산(Triclosan, C12H7Cl3O2), 염화세틸피리디늄, 폴리포스페이트(Polyphosphate) 및 플루오르화나트륨(NaF), 반코마이신(Vancomycin), 클로르헥시딘(Chlorhexidine) 및 스피라마이신(Spiramycin) 등의 항생 물질, 염화나트륨(NaCl), 알란토인클로로히드록시 알루미늄(Allantoine Chlorohydroxy Aluminum), 아미노카프론산(Aminocaproic Acid), 초산토코페롤(tocopherol acetate) 등의 합성원료, 또는 유기/무기 불소가 사용되어 왔다. 그러나 상기 방법들은 충치 예방에는 효과가 있으나, 구토, 설사 등을 일으키고, 항생물질에 대한 내성이 발생하는 단점이 있어 사용이 제한되고 있다. 특히 종래에는 충치, 치주염과 같은 세균 감염질환에 대해서 항생제의 사용이 일반적이었으나, 항생제는 인체의 유익한 세균까지 모두 해칠 뿐만 아니라, 과용할 경우 내성균의 출현, 환자의 면역능력 저하, 이에 따른 감염질환의 만성화, 균교대증 등과 같은 부작용을 유발시킨다.In order to suppress the dental caries and periodontal disease, the antibacterial substances sodium bicarbonate (NaHCO 3 ), triclosan (Triclosan, C 12 H 7 Cl 3 O 2 ), cetylpyridinium chloride, polyphosphate (Polyphosphate) and sodium fluoride (NaF) ), Antibiotics such as Vancomycin, Chlorhexidine and Spiramicin, sodium chloride (NaCl), Allantoine Chlorohydroxy Aluminum, Aminocaproic Acid, tocopherol acetate acetate), or organic / inorganic fluorine has been used. However, although the above methods are effective in preventing tooth decay, their use is limited due to the disadvantages of causing vomiting, diarrhea, and resistance to antibiotics. In particular, in the past, antibiotics have been generally used for bacterial infection diseases such as tooth decay and periodontitis, but antibiotics not only harm all of the beneficial bacteria in the human body, but when overdosed, the appearance of resistant bacteria, deterioration of the patient's immune capacity, and consequent infection of diseases It causes side effects such as chronicization and mycosis.
뿐만 아니라, 치약의 기포제로 소듐 라우릴 설페이트와 같은 계면활성제가 널리 사용되고 있으나, 이 또한 자극 및 염증 유발 성분으로 알려져 있다.In addition, a surfactant such as sodium lauryl sulfate is widely used as a foaming agent for toothpaste, but it is also known as a component causing irritation and inflammation.
따라서, 치면에 바이오필름, 즉 플라그가 형성되는 것을 효과적으로 억제하면서 안전성이 우수한 구강용 조성물에 대한 필요성은 여전히 존재한다.Therefore, there is still a need for an oral composition having excellent safety while effectively suppressing the formation of a biofilm, that is, a plaque, on the tooth surface.
이에 본 발명자들은 식물성 오일을 포함시킴으로써 치아 코팅 효과를 통하여 항균제를 포함하지 않아도 바이오필름 형성이 효과적으로 억제되고 치아 착색이 예방되며, 계면활성제에 의한 자극이 완화됨과 동시에 입술 보습에도 효과적인 구강용 조성물, 구체적으로 치약 조성물을 제공할 수 있음을 확인하고, 본 발명을 완성하게 되었다.Accordingly, the present inventors have effectively prevented the formation of biofilm, prevented tooth coloring, and prevented irritation caused by surfactants and effectively moisturized lips by including vegetable oil. It was confirmed that it can provide a toothpaste composition, and the present invention was completed.
따라서, 본 발명의 목적은 바이오필름 형성을 억제하여 충치 및 치주질환을 억제하면서 안전성이 우수한 구강용 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a composition for oral cavity having excellent safety while suppressing tooth decay and periodontal disease by inhibiting biofilm formation.
상기한 목적을 달성하기 위하여 본 발명은 식물성 오일; 고급알코올 및 고급지방산 중 1종 이상; 및 음이온 계면활성제 및 비이온 계면활성제 중 1종 이상을 유효성분으로 함유하는 바이오필름 형성 억제용 조성물을 제공한다.In order to achieve the above object, the present invention is a vegetable oil; At least one of higher alcohol and higher fatty acid; And it provides a composition for inhibiting biofilm formation containing at least one of anionic surfactant and nonionic surfactant as an active ingredient.
본 발명의 조성물은 안전성이 문제되는 항균제를 포함하지 않아 신체에 대하여 안전하면서도 효과적으로 치면 바이오필름의 형성을 억제할 수 있으며, 이와 더불어 커피, 차 등에 의한 치아 착색을 방지하고, 계면활성제에 의한 자극을 완화시켜주며, 입술 보습에도 효과적으로 작용할 수 있다.Since the composition of the present invention does not contain an antibacterial agent having a safety problem, it can suppress the formation of a biofilm when it strikes the body safely and effectively, and also prevents tooth coloring by coffee, tea, etc., and prevents irritation by a surfactant. It relieves and can effectively act on moisturizing lips.
본 발명에 따른 조성물은 식물성 오일; 고급알코올 및 고급지방산 중 1종 이상; 및 음이온 계면활성제 및 비이온 계면활성제 중 1종 이상을 유효성분으로 함유한다.The composition according to the invention comprises vegetable oils; At least one of higher alcohol and higher fatty acid; And anionic surfactants and nonionic surfactants.
본 발명에서 사용되는 식물성 오일은 치아를 코팅시켜 바이오필름 형성을 억제하고, 계면활성제 등에 의한 자극을 완화하며, 입술보호에 효과적인 것으로서, 코코넛오일, 올리브오일, 해바라기씨오일, 포도씨오일, 캐스터오일 등으로부터 선택되는 1종 이상이다.The vegetable oil used in the present invention is coated with teeth to suppress biofilm formation, to relieve irritation caused by surfactants, etc., and is effective for protecting lips, coconut oil, olive oil, sunflower seed oil, grape seed oil, castor oil, etc. It is one or more selected from.
본 발명에 있어서 식물성 오일은 조성물 총 중량에 대하여 5 내지 50중량%, 바람직하게는 10 내지 40중량%, 보다 바람직하게는 15 내지 30중량%의 양으로 함유된다. 함량이 5중량% 미만이면 치아 코팅에 의한 바이오필름 억제 및 치아착색 예방 효과를 나타내기 어렵고, 함량이 50중량% 초과이면 제형안정도가 떨어질 뿐만 아니라 기포력 및 상쾌함과 같은 사용감이 나빠지게 된다.In the present invention, the vegetable oil is contained in an amount of 5 to 50% by weight, preferably 10 to 40% by weight, more preferably 15 to 30% by weight based on the total weight of the composition. If the content is less than 5% by weight, it is difficult to exhibit a biofilm suppression and tooth coloration prevention effect by tooth coating, and if the content is more than 50% by weight, the stability of the formulation is lowered, and the feeling of use such as foaming power and freshness is deteriorated.
본 발명에 따른 조성물은 생크림과 같은 부드러운 사용감을 가지는 제형을 구현하기 위하여 제형화제로서 고급알코올 및 고급지방산 중 1종 이상을 사용한다. 본 발명에 있어서, 고급알코올은 스테아릴알코올, 세틸알코올 등으로부터 선택되는 1종 이상이고, 고급지방산은 스테아르산, 세틸산 등으로부터 선택되는 1종 이상이다.The composition according to the present invention uses at least one of higher alcohol and higher fatty acid as a formulation agent in order to realize a formulation having a soft feeling like fresh cream. In the present invention, the higher alcohol is at least one selected from stearyl alcohol and cetyl alcohol, and the higher fatty acid is at least one selected from stearic acid and cetyl acid.
본 발명에 있어서 고급알코올 및 고급지방산 중 1종 이상은 조성물 총 중량에 대하여 3 내지 15중량%, 바람직하게는 5 내지 12중량%, 보다 바람직하게는 6 내지 10중량%의 양으로 함유된다. 함량이 3중량% 미만이거나 15중량% 초과이면 치약의 페이스트제형이 형성이 안되고, 제형 안정성이 떨어지거나 구강내 자극이 존재하게 된다.In the present invention, at least one of higher alcohol and higher fatty acid is contained in an amount of 3 to 15% by weight, preferably 5 to 12% by weight, more preferably 6 to 10% by weight based on the total weight of the composition. If the content is less than 3% by weight or more than 15% by weight, paste formulation of the toothpaste is not formed, and formulation stability is poor or irritation in the oral cavity is present.
본 발명에 따른 조성물은 조밀한 기포형성을 위해 음이온 계면활성제 및 비이온 계면활성제 중 1종 이상의 계면활성제, 보다 바람직하게는 음이온 계면활성제 1종 이상과 비이온 계면활성제 1종 이상의 혼합물을 사용한다. 본 발명에 있어서, 음이온 계면활성제로는 소듐라우릴설페이트 등이 사용될 수 있고, 비이온 계면활성제로는 소르비탄 스테아레이트, 라우릴글루코사이드 등이 사용될 수 있다.The composition according to the present invention uses a mixture of one or more surfactants, more preferably one or more anionic surfactants and one or more nonionic surfactants, among the anionic surfactants and nonionic surfactants for dense foam formation. In the present invention, sodium lauryl sulfate or the like may be used as the anionic surfactant, and sorbitan stearate or lauryl glucoside or the like may be used as the nonionic surfactant.
본 발명에 있어서 계면활성제는 조성물 총 중량에 대하여 0.5 내지 5중량%, 바람직하게는 1 내지 4.5중량%, 보다 바람직하게는 1.5 내지 4중량%의 양으로 함유된다. 함량이 0.5중량% 미만이거나 5중량% 초과이면 치약의 페이스트제형이 형성이 잘 안되고, 제형 안정성이 떨어지거나 구강내 자극이 존재하게 된다.In the present invention, the surfactant is contained in an amount of 0.5 to 5% by weight, preferably 1 to 4.5% by weight, more preferably 1.5 to 4% by weight based on the total weight of the composition. If the content is less than 0.5% by weight or more than 5% by weight, the paste formulation of the toothpaste is not well formed, and the formulation stability is poor or irritation in the oral cavity is present.
본 발명에 따른 조성물은 치면 바이오필름 형성을 억제하는 것이 목적이라면 그 제형에 있어서 특별히 한정되지 않는다. 구체적으로 구강 청결용 제품, 예를 들면, 치약, 구강용 세정제, 구강 스프레이, 구강 세정용 티슈, 치아 미백제 등의 제품으로 제형화될 수 있으며, 바람직하게는 치약으로 제형화될 수 있다.The composition according to the present invention is not particularly limited in its formulation as long as it is intended to suppress the formation of a biofilm upon tooth. Specifically, it may be formulated as a product for oral cleansing, for example, toothpaste, mouthwash, mouth spray, tissue for mouthwash, tooth whitening agent, and preferably toothpaste.
본 발명에 따른 조성물은 제형 및 사용 목적에 따라 통상적으로 사용하는 연마제, 습윤제, 보조 기포제, 결합제, 감미제, pH 조절제, 방부제, 약효성분, 향료, 증백제, 색소, 용제 등을 함유할 수 있다.The composition according to the present invention may contain abrasives, wetting agents, auxiliary foaming agents, binders, sweeteners, pH adjusting agents, preservatives, active ingredients, fragrances, brighteners, pigments, solvents, etc., which are commonly used depending on the formulation and purpose of use.
본 발명에 따른 조성물은 상기와 같은 식물성 오일; 고급알코올 또는 고급지방산; 및 음이온 또는 비이온 계면활성제를 유효성분으로 함유함으로써 치면 바이오필름 형성 억제 효과가 뛰어나고, 커피, 차 등에 의한 치아 착색 예방에도 효과적이며, 계면활성제의 사용에 따른 자극도 상당히 완화된다. 뿐만 아니라, 생크림과 같은 질감을 가지고 부드럽게 치아에 도포되며, 사용시 거품이 조밀하고, 사용 후에는 치아뿐만 아니라 입술에도 보습감을 주어 부드러운 느낌을 부여한다.The composition according to the present invention is a vegetable oil as described above; Higher alcohol or higher fatty acid; And by containing an anionic or nonionic surfactant as an active ingredient, the effect of inhibiting the formation of a biofilm is excellent, it is also effective in preventing tooth coloring by coffee, tea, etc., and the irritation caused by the use of the surfactant is also significantly reduced. In addition, it has the same texture as fresh cream and is gently applied to the teeth. When used, the foam is dense, and after use, it gives a moisturizing feeling to the lips as well as the teeth to give a soft feeling.
이하에서는 시험예 및 제조예를 들어 본 발명의 구성 및 효과를 보다 구체적으로 설명한다. 그러나 이들 시험예 및 제조예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 발명의 범주 및 범위가 하기 예에 의해 제한되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to test examples and manufacturing examples. However, these test examples and manufacturing examples are provided for illustrative purposes only to aid understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.
[참고예] 실시예 및 비교예의 제조[Reference Example] Preparation of Examples and Comparative Examples
하기 표 1 내지 5의 조성으로 비교예 1 내지 12 및 실시예 1 내지 23의 치약 조성물을 업계의 통상적인 방법으로 제조하였다.Toothpaste compositions of Comparative Examples 1 to 12 and Examples 1 to 23 with the compositions of Tables 1 to 5 below were prepared by conventional methods in the industry.
알코올
&
고급
지방산Advanced
Alcohol
&
Advanced
fatty acid
알코올
&
고급
지방산Advanced
Alcohol
&
Advanced
fatty acid
&
고급지방산High-grade alcohol
&
High-grade fatty acids
&
고급지방산High-grade alcohol
&
High-grade fatty acids
&
고급지방산High-grade alcohol
&
High-grade fatty acids
[시험예 1] 제형 안정성 평가[Test Example 1] Formulation stability evaluation
상기 참고예에서 제조한 실시예 1 내지 23 및 비교예 1 내지 12의 조성물에 대하여 페이스트 형태로 제형화도, 제형안정도를 평가하였다.The formulations of Examples 1 to 23 and Comparative Examples 1 to 12 prepared in the reference example were evaluated for formulation degree and formulation stability in paste form.
안정도 평가를 통해 0℃, 45℃, 60℃도, 사이클링 테스트(-10℃ ~ 45℃, 11시간씩 유지)에서 4주간 변색, 변취, 분리 등이 일어나는지 여부를 확인하였다.Through the stability evaluation, it was confirmed whether discoloration, deodorization, separation, etc. occurred for 4 weeks in a 0 ° C, 45 ° C, 60 ° C, cycling test (-10 ° C to 45 ° C, maintained for 11 hours).
구체적으로, 페이스트 형태의 제형화가 이루어진 경우에는 O, 이루어지지 않은 경우에는 X로 평가하였고, 제형의 분리가 일어나지 않아 제형이 안정적인 경우에는 O, 분리가 일어난 경우에는 X로 평가하였다. 평가 결과는 하기 표 6에 기재하였다.Specifically, when the formulation in the form of a paste was made, it was evaluated as O, and when not, it was evaluated as X. When separation of the formulation did not occur, it was evaluated as O when the formulation was stable, and as X when separation occurred. Table 6 below shows the evaluation results.
제형화Paste form
Formulation
제형화Paste form
Formulation
제형화Paste form
Formulation
상기 표 6에 나타낸 바와 같이, 고급알코올과 고급지방산의 함량이 적정 범위를 벗어난 비교예 4 및 5의 경우에는 페이스트 형태로의 제형화가 잘 이루어지지 않았으며, 계면활성제의 함량이 적정 범위 미만인 비교예 6의 경우와 오일 함량이 적정 범위를 벗어난 비교예 9의 경우에는 제형의 분리가 일어났다.As shown in Table 6, in the case of Comparative Examples 4 and 5 in which the content of the higher alcohol and higher fatty acid was outside the appropriate range, the formulation in the form of a paste was not well performed, and the comparative example in which the content of the surfactant was less than the proper range In the case of 6 and Comparative Example 9 in which the oil content was outside the appropriate range, separation of the formulation occurred.
상기 평가 결과를 기초로 하여, 이하의 시험예에서는 비교예 1 내지 3, 7, 8, 10 내지 12, 그리고 실시예 1 내지 23에 대하여 효능 검증 및 실험을 실시하였다.Based on the evaluation results, in the following test examples, efficacy verification and experiments were conducted for Comparative Examples 1 to 3, 7, 8, 10 to 12, and Examples 1 to 23.
[시험예 2] 바이오필름 형성 억제 효과 평가(In-vitro)[Test Example 2] Evaluation of biofilm formation inhibitory effect (In-vitro)
상기 참고예에서 제조한 비교예 1 내지 3, 7, 8, 10 내지 12, 그리고 실시예 1 내지 23 각각에 있어서 바이오필름 형성 억제능을 평가하는 인-비트로 실험(In-vitro test)을 치아 모사물질인 하이드록시아파타이트 디스크(Biotek社)를 이용하여 진행하였다.In Comparative Examples 1 to 3, 7, 8, 10 to 12, and Examples 1 to 23 prepared in the reference example, an in-vitro test for evaluating the biofilm formation inhibitory ability in each of the examples is a tooth simulating material. Phosphorus hydroxyapatite disk (Biotek) was used.
a) 스트렙토코커스 뮤탄스(Streptococcus mutans, KCTC 3065) 균을 Brain Heart infusion broth(Difco, BD Biosciences)에 접종한 후 35℃ 배양기(Imperial lll Incubator, Lab Line Instruments Inc.)에서 24시간 동안 배양하였다.a) Streptococcus mutans (KCTC 3065) bacteria were inoculated in Brain Heart infusion broth (Difco, BD Biosciences) and cultured in a 35 ° C incubator (Imperial lll Incubator, Lab Line Instruments Inc.) for 24 hours.
b) 하이드록시아파타이트 디스크를 70% 에탄올에 30분간 담지하여 멸균한 후, 멸균이온수로 3회 세정하였다.b) The hydroxyapatite disc was sterilized by supporting it in 70% ethanol for 30 minutes, and then washed three times with sterile ionized water.
c) 세정한 하이드록시아파타이트 디스크를 24웰 플레이트(BD Falcon)에 한 개씩 넣고, 완전히 건조시켰다.c) Washed hydroxyapatite discs are placed one by one in a 24-well plate (BD Falcon) and dried completely.
d) 비교예 1 내지 3, 7, 8, 10 내지 12, 그리고 실시예 1 내지 23 샘플 각각을 이온수로 20% 희석한 후 1mL를 취하여 하이드록시아파타이트 디스크가 담긴 웰에 분주하여 3분 동안 처리하였다.d) Comparative Examples 1 to 3, 7, 8, 10 to 12, and each of Examples 1 to 23 samples were diluted by 20% with ionic water and 1 mL was taken and dispensed into wells containing hydroxyapatite discs and treated for 3 minutes. .
e) 멸균 이온수로 하이드록시아파타이트 디스크를 세정하여 남아 있는 샘플을 제거하였다.e) The hydroxyapatite disc was rinsed with sterile ionized water to remove the remaining sample.
f) 하이드록시아파타이트 디스크를 다른 24웰 플레이트로 옮긴 후, 1% 수크로스가 함유된 Brain Heart infusion broth를 각각의 웰에 1mL씩 넣고 균 배양액 1μL를 접종하였다.f) After transferring the hydroxyapatite disc to another 24-well plate, 1 ml of Brain Heart infusion broth containing 1% sucrose was added to each well, and 1 μL of the bacterial culture was inoculated.
g) 균이 접종된 24웰 플레이트를 35℃ 배양기에서 3일간 배양하여 바이오필름을 형성시켰다.g) The 24-well plate inoculated with the bacteria was cultured in a 35 ° C incubator for 3 days to form a biofilm.
h) 3일 후 균 증식 여부를 관찰하고, 멸균 이온수로 하이드록시아파타이트 디스크를 세정한 후 0.1% Crystal violet 용액(Sigma)을 1mL씩 분주하여 30분 동안 염색하였다.h) After 3 days, the growth of bacteria was observed, and after washing the hydroxyapatite disc with sterile ionized water, 1 mL of 0.1% Crystal violet solution (Sigma) was dispensed at 1 mL and stained for 30 minutes.
i) 하이드록시아파타이트 디스크를 멸균 이온수로 세정한 후 상온에서 완전히 건조시켰다.i) The hydroxyapatite disc was washed with sterile ionized water and then dried completely at room temperature.
j) 70% 에탄올 1mL를 넣고 염색된 하이드록시아파타이트 디스크가 백색으로 탈색될 때까지 염료를 추출하였다.j) 1 mL of 70% ethanol was added, and the dye was extracted until the dyed hydroxyapatite disc was discolored to white.
l) 추출액을 1/2 단계별로 희석한 후, 분광광도계(Spectramax 190, Molecular Devices Corporation)를 이용하여 흡광도를 측정하였다(OD 590 nm).l) After diluting the extract in 1/2 steps, the absorbance was measured using a spectrophotometer (Spectramax 190, Molecular Devices Corporation) (OD 590 nm).
m) 측정치에서 Blank well의 값을 빼고 2 이하 수치로 측정된 희석비율 값을 선택하여 바이오필름 형성 억제능을 계산하였다m) By subtracting the value of the blank well from the measured value and selecting the dilution ratio value measured with a value of 2 or less, the ability to inhibit biofilm formation was calculated.
결과는 하기 표 7에 나타내었다.The results are shown in Table 7 below.
10Comparative example
10
상기 표 7에 나타낸 바와 같이, 코코넛오일 및 항균제를 포함하지 않은 비교예 1, 3, 10 내지 12, 및 코코넛오일의 함량이 적정 범위 미만인 비교예 8의 경우 바이오필름 억제 효과가 상당히 낮은 것으로 나타났다. 기존 제품에서 사용되어 오던 항균제인 염화세틸피리디늄을 포함한 비교예 2 또한 식물성 오일을 15중량% 이상의 양으로 함유한 실시예보다 바이오필름 억제 효과가 낮게 나타났다. 반면, 본원발명에서 치아코팅제로서 사용되는 코코넛오일, 올리브 오일 등의 식물성 오일을 모두 함유한 비교예 7과 실시예는 모두 비교예 1 및 3에 비하여 바이오필름 형성 억제 효과가 상당히 높은 것으로 나타났다.한편, 항균제인 염화세틸피리디늄을 포함하고 코코넛오일을 함유하지 않은 비교예 2와 실시예를 비교하면, 코코넛 오일을 5중량% 함유하는 실시예 2의 경우에는 항균 효과가 더 낮은 것으로 나왔으나, 코코넛오일 및 올리브오일을 15중량% 이상 함유하는 실시예 2를 제외한 나머지 실시예에서는 비교예 2보다 유사하거나 더 좋은 바이오필름 형성 억제 효과를 보임을 확인할 수 있다.As shown in Table 7, Comparative Example 1, 3, 10 to 12 without coconut oil and an antibacterial agent, and Comparative Example 8 in which the content of coconut oil was less than an appropriate range was found to have a significantly low biofilm inhibitory effect. Comparative Example 2 including cetylpyridinium chloride, an antibacterial agent that has been used in existing products, also showed a lower biofilm inhibitory effect than the example containing vegetable oil in an amount of 15% by weight or more. On the other hand, in Comparative Example 7 and Examples containing both vegetable oils such as coconut oil and olive oil used as a tooth coating agent in the present invention, both of Comparative Examples 1 and 3 showed that the effect of inhibiting biofilm formation was significantly higher. , Compared to Comparative Example 2 and Example containing the antibacterial agent cetylpyridinium chloride and not containing coconut oil, in Example 2 containing 5% by weight of coconut oil, the antibacterial effect was found to be lower, but coconut It can be seen that in the other examples except Example 2 containing 15% by weight or more of oil and olive oil, the biofilm formation inhibitory effect is similar or better than that of Comparative Example 2.
[시험예 3] 치아착색 예방 효과 평가(In-vitro)[Test Example 3] To evaluate the effect of preventing tooth pigmentation (In-vitro)
상기 참고예에서 제조한 비교예 1, 3 그리고 실시예 1, 2, 4, 6, 10, 13 샘플에 대해 치아착색 억제능을 평가하는 인-비트로 실험(In-vitro test)을 치아 모사물질인 하이드록시아파타이트 디스크(Biotek社)를 이용하여 진행하였다.In Comparative Examples 1, 3 and Examples 1, 2, 4, 6, 10, 13 prepared in the reference example, an in-vitro test for evaluating the ability to inhibit tooth pigmentation was measured. Loxiapatite discs (Biotek) were used.
a) 하이드록시아파타이트 디스크의 명도(Lightness)를 ShadeEye-EX(Shofu Dental corporation)를 이용하여 초기값을 측정하였다.a) The initial value of the hydroxyapatite disc was measured using ShadeEye-EX (Shofu Dental corporation).
b) 브러싱머신을 이용하여 3분 동안 비교예 1, 3 그리고 실시예 1, 2, 4, 6, 10, 13 샘플 각각을 디스크에 적용한 다음 30초간 흐르는 물로 세척하였다.b) Each of the samples of Comparative Examples 1, 3 and Examples 1, 2, 4, 6, 10, 13 was applied to the disk for 3 minutes using a brushing machine, and then washed with running water for 30 seconds.
c) 세척한 하이드록시아파타이트 디스크를 아메리카노 커피에 담지시킨 후, 4시간, 8시간 경과시 3개씩 꺼내어 명도 변화값을 측정하였다.c) After washing the hydroxyapatite discs in Americano coffee, 3 of them were taken out after 4 hours and 8 hours to measure the change in brightness.
측정 결과는 하기 표 8에 나타내었다.The measurement results are shown in Table 8 below.
13Example
13
상기 표 8에 나타낸 바와 같이, 치아착색 예방에 음이온 계면활성제의 종류가 영향을 미치는지 여부를 알아보기 위하여 포함시킨 계면활성제의 종류를 달리하여 제조한 비교예 1 및 3은 착색 예방에 있어서 큰 차이를 보이지 않았다.반면, 코코넛오일 등과 같은 오일을 함유하는 실시예들의 경우 코코넛오일을 포함하지 않는 비교예 1 및 3에 비하여 높은 치아착색 예방 효과를 나타내었다. 특히, 치아착색 예방 효과는 착색물질을 적용하고 8시간 정도 지난 후에 유의적인 차이를 보였다.As shown in Table 8, Comparative Examples 1 and 3 prepared by different types of surfactants included in order to find out whether or not the type of the anionic surfactant affects the prevention of tooth coloration have significant differences in the prevention of coloring. On the other hand, in the case of the examples containing oil, such as coconut oil, it showed a high tooth coloring prevention effect compared to Comparative Examples 1 and 3, which does not contain coconut oil. In particular, the tooth coloring prevention effect showed a significant difference after about 8 hours after applying the coloring material.
[시험예 4] 구강 자극성 평가(In-vitro)[Test Example 4] Oral irritation evaluation (In-vitro)
상기 참고예에서 제조한 비교예 1, 2, 3, 7과 실시예 1, 2, 4, 6, 10, 13 각각에 있어서 구강 자극 정도를, Agar diffusion assay 시험법(ISO 10993-5:2009 (E) Biological evaluation of medical device Part 5 test for in vitro cytotoxicity: Agar diffusion assay)을 이용하여 평가하였다.In Comparative Examples 1, 2, 3, 7 and Examples 1, 2, 4, 6, 10, 13 prepared in the reference example, the oral stimulation degree was measured in the Agar diffusion assay test method (ISO 10993-5: 2009 ( E) Biological evaluation of medical device Part 5 test for in vitro cytotoxicity: Agar diffusion assay).
a) L929(Mouse fibroblast, ACTT, USA) 세포를 10% FBS와 1% 페니실린-스트렙토마이신 함유 RPMI-1640 배지(Gibco, USA)와 함께 6웰 플레이트에 각 웰당 1×105개씩의 밀도로 2ml씩 분주하고, 이를 5% CO2, 37℃조건에서 24시간 동안 배양하였다.a) 2 ml of L929 (Mouse fibroblast, ACTT, USA) cells with 10% FBS and 1% penicillin-streptomycin RPMI-1640 medium (Gibco, USA) at a density of 1 × 10 5 per well in a 6-well plate Each was dispensed and incubated for 24 hours at 5% CO 2 , 37 ° C.
b) 24시간 후 세포가 웰내에서 80% 이상의 단일세포층을 형성하면 배양액을 걷어내고 1.5% 아가로스(Sigma-Aldrich), 10% FBS(Gibco) 및 0.0033% 뉴트럴 레드(Neutral red)(Sigma-Aldrich)가 함유된 50℃의 페놀 무함유 DMEM(Gibco) 배지를 2ml씩 분주하고, 이를 45분간 5% CO2, 37℃조건에서 굳혔다.b) After 24 hours, when the cells form a single cell layer of 80% or more in the well, the culture is removed and 1.5% agarose (Sigma-Aldrich), 10% FBS (Gibco), and 0.0033% Neutral red (Sigma-Aldrich) ) Containing 50 ml of phenol-free DMEM (Gibco) medium at 2 ° C was dispensed by 2 ml, and this was solidified at 5% CO 2 and 37 ° C for 45 minutes.
c) 비교예 1, 2, 3, 7과 실시예 1, 2, 4, 6, 10, 13 각각을 RPMI-1640 배지에 25%로 희석한 시험물질을 지름 8mm 종이 디스크(Advantec, Japan)에 15μl씩 분주하여 적시고, 적신 종이 디스크를 b)에서 굳힌 아가로스 위에 얹은 다음, 5% CO2, 37℃조건에서 24시간 동안 배양하였다.c) Comparative Examples 1, 2, 3, 7 and Examples 1, 2, 4, 6, 10, 13, each of the test substances diluted 25% in RPMI-1640 medium on an 8 mm diameter paper disk (Advantec, Japan) 15 μl was dispensed and moistened, and the soaked paper disc was placed on the agarose solidified in b), and then cultured at 5% CO 2 at 37 ° C. for 24 hours.
d) 종이 디스크로부터 생성된 환의 가장자리까지의 거리를 15cm 자를 이용하여 측정하였다.d) The distance from the paper disc to the edge of the resulting ring was measured using a 15 cm ruler.
측정 결과는 하기 표 9에 나타내었다.The measurement results are shown in Table 9 below.
(mm)Agarose bleaching
(mm)
상기 표 9에 나타낸 바와 같이, 글루타메이트 계열의 계면활성제를 함유한 비교예 3이 구강 자극이 가장 적은 것으로 나타났다.한편, 비교예 1과 실시예 1, 2, 4, 6, 10, 13을 비교하면, 이들은 모두 같은 함량의 소듐 라우릴 설페이트를 함유하지만, 구강 자극 정도에 있어서는 차이를 보였으며, 특히 실시예의 경우가 자극이 낮은 것을 확인할 수 있다. 이를 통해, 코코넛오일이 설페이트 계열의 계면활성제에 의한 자극을 완화시키는데 도움을 주는 것을 예상할 수 있다.As shown in Table 9, Comparative Example 3 containing a glutamate-based surfactant showed the lowest oral irritation. On the other hand, when comparing Comparative Example 1 with Examples 1, 2, 4, 6, 10, 13 , These all contain the same amount of sodium lauryl sulfate, but showed a difference in the degree of oral irritation, and it can be confirmed that the irritation is low especially in the case of the Examples. Through this, it can be expected that coconut oil helps to alleviate irritation caused by sulfate-based surfactants.
그러나, 비교예 7을 보면, 계면활성제 함량이 5중량%를 넘게 되면, 코코넛오일에 의한 자극 완화 효과는 미비하다는 것을 알 수 있다.However, in Comparative Example 7, when the surfactant content exceeds 5% by weight, it can be seen that the effect of alleviating irritation by coconut oil is insufficient.
[시험예 5] 관능평가[Test Example 5] Sensory evaluation
치약제품에 대한 사용감 평가 훈련을 통해 구성된 전문패널을 통해 관능평가를 진행하였다. 상기 참고예에서 제조한 비교예 1, 실시예 1, 2, 4, 6, 10, 13에 대하여, 전문패널 10명이 7가지 제품을 각각 3일씩 3주간 하루 3번 양치한 후에 9점 만점으로 평가하도록 하였다. 평가 결과는 하기 표 10에 나타내었다.Sensory evaluation was conducted through a specialized panel composed through the evaluation of the feeling of use for toothpaste products. With respect to Comparative Example 1, Example 1, 2, 4, 6, 10, and 13 prepared in the reference example, 10 expert panelists rated 7 products after brushing 7 products 3 times a day for 3 weeks, 3 times each, and then rated them with a score of 9 Was made. The evaluation results are shown in Table 10 below.
상기 표 10의 평가 결과로부터 알 수 있는 바와 같이, 기포력의 경우 오일이 함유되어 있지 않은 비교예 1이 높았고, 실시예 1, 2, 4, 6, 10, 13 중에서는 비교적 적은 양의 오일을 함유하는 실시예 2의 경우가 비교적 높게 나타난 반면, 비교적 많은 양의 오일을 함유하는 실시예 4는 기포력이 낮은 것으로 나타나, 오일 함량과 기포력은 상당한 상관관계가 있음을 확인할 수 있었다.반면, 부드러움면에서는 실시예 1, 2, 4, 6, 10, 13의 경우가 비교예 1에 비하여 현저하게 우수하였다.As can be seen from the evaluation results in Table 10, in the case of bubble power, Comparative Example 1, which did not contain oil, was high, and among Examples 1, 2, 4, 6, 10, 13, a relatively small amount of oil was used. In the case of Example 2 containing relatively high, while Example 4 containing a relatively large amount of oil appeared to have low foaming power, it was confirmed that there was a significant correlation between the oil content and foaming power. In terms of softness, Examples 1, 2, 4, 6, 10, and 13 were significantly superior to Comparative Example 1.
또한, 입술 보습 면에서 오일이 함유된 실시예 1, 2, 4, 6, 10, 13의 경우 모두 보습력이 우수한 것으로 나타났다. In addition, in the case of Examples 1, 2, 4, 6, 10, and 13 containing oil in terms of moisturizing lips, it was found that the moisturizing power was excellent.
이러한 평가결과로부터 본 발명에 따른 구강용 조성물은 사용시 거품이 조밀하여 치아에 부드럽게 도포되고, 사용 후에는 치아뿐만 아니라 입술에도 부드러운 느낌을 부여할 수 있으며, 따라서 바이오필름의 생성을 효과적으로 억제하면서 계면활성제에 의한 자극도 적고, 입술 보호에도 효과적이라는 점에서 종래 구강용 제품과는 구별되는 새로운 이점을 가질 수 있다.From these evaluation results, the oral composition according to the present invention has a dense foam when used and is gently applied to the teeth, and after use can impart a soft feeling to the lips as well as the teeth. Since it is less irritating and effective in protecting lips, it may have a new advantage that is distinguished from conventional oral products.
[제형예 1] 구강용 세정제[Formulation Example 1] Mouthwash
[제형예 2] 치아 미백제[Formulation Example 2] Teeth whitening agent
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910870248.6A CN110897935B (en) | 2018-09-17 | 2019-09-16 | Composition for inhibiting biofilm formation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180110991 | 2018-09-17 | ||
KR1020180110991 | 2018-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20200031990A true KR20200031990A (en) | 2020-03-25 |
Family
ID=70001883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190102815A KR20200031990A (en) | 2018-09-17 | 2019-08-22 | Composition for inhibiting a formation of biofilm |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20200031990A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9114097B1 (en) | 2014-12-31 | 2015-08-25 | Babak Aminpour | Composition of natural toothpaste |
-
2019
- 2019-08-22 KR KR1020190102815A patent/KR20200031990A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9114097B1 (en) | 2014-12-31 | 2015-08-25 | Babak Aminpour | Composition of natural toothpaste |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030219390A1 (en) | Liquid tooth whitening composition | |
JP2007515427A (en) | Compositions and methods for preventing or reducing plaque and / or gingivitis using a bioactive glass-containing dentifrice | |
TW201538175A (en) | Oral care compositions and methods | |
WO2014098870A1 (en) | Oral care composition | |
US20240156903A1 (en) | Oral Composition and Methods | |
EP2399576B1 (en) | Use of antibacterial compounds for the oral cavity hygiene | |
ES2968015T3 (en) | Oral care composition | |
TWI659747B (en) | Oral care compositions and methods | |
KR20130116486A (en) | Oral composition for inhibiting dental plaque | |
KR100951396B1 (en) | Dental composition for antiplaque and antigingivity | |
KR101756306B1 (en) | Oral composition containing extract of sapindus mukurossi Gaertn | |
KR20200031990A (en) | Composition for inhibiting a formation of biofilm | |
US20230404870A1 (en) | A fluoride dentifrice containing an iodine component | |
CN110897935B (en) | Composition for inhibiting biofilm formation | |
KR102664431B1 (en) | Oral composition for preventing dental caries | |
KR20180075987A (en) | Oral composition comprising fermented green tea extract having excellent antibacterial effect on oral bacteria and anti-inflammatory effect | |
KR20170051006A (en) | Oral composition containing both isopropylmethylphenol and oral tissue astringent | |
KR102635197B1 (en) | Oral composition for effective prevention of biofilm formation | |
KR100659139B1 (en) | Oral composition having a good antibacterial effect | |
JP6435852B2 (en) | Oral composition and method for preventing discoloration of oral composition | |
CN115804732B (en) | Whitening and tooth protecting composition and gargle thereof | |
Evans et al. | Interference of antimicrobial activity of combinations of oral antiseptics against Streptococcus mutans, Streptococcus sanguinis, and Lactobacillus acidophilus | |
KR20180081271A (en) | Oral composition for removing dental plaque containing alkyl glucoside | |
KR100963301B1 (en) | Toothpaste composition comprising hemp fiber | |
KR20240030235A (en) | Hydro hydrogen toothpaste |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal |